Eliminating HIV-1 reservoirs.
HIV-1 infection can now be treated effectively in many patients in the developed world, using combination antiretroviral therapeutics, called highly active antiretroviral therapy (HAART). Nevertheless, these regimens do not cure HIV-1 infection. Residual disease is maintained via proviral latency in resting CD4+ T-lymphocytes and possibly monocytes/macrophages. In addition, low-level viral replication continues in a cryptic manner during HAART. As such, a variety of approaches to both activate the latent reservoirs and deplete residual viral replication are being developed. In understanding the molecular pathogenesis of HIV-1 disease, one can potentially target these cellular reservoirs of HIV-1 persistence.
Pomerantz
Roger J
RJ
Thomas Jefferson University, Philadelphia, PA 19107, USA. roger.j.pomerantz@mail.tju.edu
D019380:Anti-HIV Agents / Q000627:therapeutic use; D023241:Antiretroviral Therapy, Highly Active; D015496:CD4-Positive T-Lymphocytes / Q000821:virology; D004197:Disease Reservoirs; D015658:HIV Infections / Q000188:drug therapy / Q000517:prevention & control*; D015497:HIV-1; D006801:Humans
D019380:Anti-HIV Agents